Nevertheless, it should be emphasized that potential AP-1/GGA2 targeting as an anti-cancer strategy is not dependent on activation mutations but on the intracellular recycling of EGFR, and that AP-1/GGA2 targeting could arrest multiple cancer-related signaling pathways that originate from different RTKs. The gene discussed is GGA2; the disease is cancer.